We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Whole Blood Controls Monitor Immunosuppressant Drug Test Precision

By LabMedica International staff writers
Posted on 29 Oct 2012
A lyophilized, third party, human whole blood based control offers five individual levels and includes Cyclosporine, Tacrolimus, and Sirolimus.

The control can be used with immunoassay or chromatographic techniques. More...
Called the Lyphochek Whole Blood Immunosuppressant Control, it was designed for use as an assayed quality control material to monitor the precision of immunosuppressant drug test procedures in the clinical laboratory from low to very high concentrations. Immunosuppressant drugs are typically used in transplant therapy to help minimize organ rejection. Lyphochek Control is supplied as a whole blood based material that can be processed in the same manner as patient samples.

Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a manufacturer and distributor of life science clinical diagnostics and research products, released the Lyphochek Whole Blood Immunosuppressant Control.

The company offers technical support and troubleshooting assistance for the control. The Unity Interlaboratory Program and the Unity Real Time, a data management-software solution designed to improve the effectiveness of quality control processes, are available for use with the Lyphochek Control.

Related Links:

Bio-Rad Laboratories - TDM controls
Bio-Rad Laboratories, Inc.



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gel Cards
DG Gel Cards
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
Image: (A) Normal skin and (B) possible pathology in ALS skin (Photo courtesy of Biomolecules and Biomedicine (2025) DOI: 10.17305/bb.2025.12100)

Skin-Based Biomarkers to Enable Early Diagnosis of Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, causing muscle weakness, paralysis, and death within three to five... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.